Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company focused on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease, as well as rare skeletal muscle, cardiac, and metabolic muscle diseases. The company uses its FORCE platform to deliver disease-modifying therapeutics. Dyne Therapeutics was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne advances DMD drug toward FDA decision, funds pipeline
▲
FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.
This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.
▲
New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.
This is a new pipeline expansion that increases the company's long-term value proposition.
◆
Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.
This is a major capital event that affects the share count and near-term stock price, and is new information.
▲
Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.
This is a new financing event that improves liquidity and reduces reliance on equity dilution.
Q3 2026
▲3
Dyne advances DMD drug toward FDA decision, funds pipeline
▲
FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.
This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.
▲
New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.
This is a new pipeline expansion that increases the company's long-term value proposition.
◆
Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.
This is a major capital event that affects the share count and near-term stock price, and is new information.
▲
Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.
This is a new financing event that improves liquidity and reduces reliance on equity dilution.
News & notes movingDYN
SwitzerlandUnited States
DYN▼impact 4
Novartis twin drug setbacks pressure pipeline and CEO
Novartis said its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days, sending shares down about 9% in one of its worst trading days on record. The failure of del-desiran, acquired through the recent $12 billion purchase of Avidity, increases pressure on CEO Vas Narasimhan and his M&A strategy. The drug was being tested for myotonic dystrophy, a disease with no approved treatments, and analysts had estimated peak annual sales of $3.1 billion with a 60% chance of success. The slide wiped about 24 billion Swiss francs ($29.6 billion) off market value, and shares of Dyne Therapeutics and Sarepta Therapeutics fell 30% and 15.5% respectively. Novartis reiterated its full-year guidance, expecting sales to grow at a compound annual rate of 5% to 6% between 2025 and 2030.
NOVN.SW · Capital · Negative The failure of a drug from the $12 billion Avidity acquisition pressures CEO Narasimhan and his M&A strategy, wiping ~24 billion Swiss francs off market value.
NOVN.SW · Technology · Negative Novartis's del-desiran failed a late-stage myotonic dystrophy trial, its second major pipeline setback in days.
DYN · Competition · Negative Dyne shares fell 30% as Novartis's del-desiran failure in myotonic dystrophy hit sentiment on rival developers in the same space.
SRPT · Competition · Negative Sarepta shares fell 15.5% amid the read-across from Novartis's failed muscle-wasting drug trial.
Novartis shares plunge 13% after muscle drug trial fails
Novartis shares fell 13% in premarket trading on Tuesday after its late-stage trial for the muscle-wasting drug del-desiran failed to meet primary endpoints, marking the company's third drug trial setback in a week and putting the stock on track for its worst trading day ever. The failure also dragged down other biotech stocks, with Dyne Therapeutics falling about 30%, Sarepta Therapeutics dropping 16%, and NewAmsterdam Pharma down 12%, as concerns spread across the sector. Novartis said its global phase III HARBOR study, testing del-desiran in patients with myotonic dystrophy type 1, did not demonstrate statistically significant improvement versus placebo on measurements of hand opening time. The company is evaluating the full dataset and will engage with health authorities to determine the next steps. Del-desiran is one of three antibody oligonucleotide conjugate therapies added to Novartis's neuromuscular pipeline through its roughly $12 billion acquisition of Avidity Biosciences last year. Despite the setback, Novartis maintains its 5-6% five-year sales CAGR guidance for 2025-2030.
Biotech & Genomic Medicine › RNA Therapeutics ▼Technology
NOVN.SW · Technology · Negative Novartis's phase III HARBOR trial for del-desiran failed to meet primary endpoints, its third trial setback in a week.
Avidity Biosciences · Technology · Negative Del-desiran was one of three antibody oligonucleotide conjugate therapies acquired via Novartis's ~$12 billion Avidity Biosciences acquisition, so the trial failure undermines that pipeline asset.
DYN · Competition · Negative Dyne Therapeutics fell about 30% as the Novartis muscle-drug trial failure spread concerns across the biotech sector.
Biotech Stocks Hit 52-Week Highs on Earnings and Pipeline Updates
Several biotech stocks reached 52-week highs on August 11, 2026, driven by quarterly reports and regulatory progress. Alamar Biosciences surged over 30% to $38.54 after reporting second-quarter revenue of $29.43 million and projecting full-year 2026 revenue between $116 million and $120 million. Dyne Therapeutics rose to $27.13 following FDA acceptance of its Biologics License Application for Z-Rostudirsen, with a decision expected in January 2027. Cullinan Therapeutics gained over 7% to $19.82 after narrowing its quarterly loss and announcing plans for Phase 2 trials in autoimmune diseases. Cardinal Health climbed to $258.30 on fiscal 2026 revenue of $254.2 billion and net earnings of $1.7 billion. DexCom reached $89.56 after reporting 13% second-quarter revenue growth to $1.31 billion and forecasting full-year revenue of $5.18 billion to $5.25 billion.
Dyne Therapeutics reports Q2 GAAP EPS of -$1.08, missing estimates by $0.33
Dyne Therapeutics reported a second-quarter GAAP loss of $1.08 per share, missing analyst estimates by $0.33. The company held cash, cash equivalents, and marketable securities of $898.5 million as of June 30, 2026. In July 2026, Dyne completed an underwritten public offering of 21,045,000 shares of common stock, generating estimated net proceeds of approximately $405.0 million. Management expects that its June 30 cash position combined with the offering proceeds will be sufficient to fund operations into the second quarter of 2028.
Dyne Therapeutics Gets FDA Clearance for DYNE-302 IND in FSHD
Dyne Therapeutics has received U.S. FDA clearance for its investigational new drug application to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy. DYNE-302 is the company's third program to enter clinical development using its FORCE platform, which also underpins its Duchenne muscular dystrophy and myotonic dystrophy type 1 candidates. The Phase 1 trial will be a randomized, placebo-controlled, double-blind, multiple ascending dose study in ambulatory adults with FSHD, with safety and tolerability as the primary endpoint. In the first cohort, nine participants will receive three intravenous doses every four weeks, randomized two-to-one to DYNE-302 at 1.5 milligrams per kilogram or placebo. Dyne intends to pursue a traditional approval pathway in the U.S. for DYNE-302, which is designed to suppress DUX4 expression using a TfR1-targeting Fab and siRNA payload.
Dyne Therapeutics grants inducement equity awards to 12 new employees
Dyne Therapeutics has granted inducement equity awards to 12 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards consist of non-statutory stock options to purchase up to an aggregate of 358,600 shares of common stock at an exercise price equal to the July 21, 2026 closing price, and restricted stock units covering an aggregate of 116,500 shares. The stock options have a ten-year term and vest over four years, with 25% after one year and the remainder in 12 quarterly installments, while the restricted stock units vest in four equal annual installments, both subject to continued service. The grants were made under Dyne’s 2024 Inducement Stock Incentive Plan.
Dyne Therapeutics shares drop after pricing $375 million public offering
Dyne Therapeutics shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximately $375 million. The offering was priced at $20.50 per share, a discount of about 14% to Tuesday's closing price of $23.83. Dyne priced an upsized offering of 18.3 million shares, with gross proceeds estimated at $375.15 million before underwriting discounts and expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2.745 million shares. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are joint book-running managers, with Jones as lead manager. The offering is expected to close on or around July 23, 2026.
FDA Accepts Dyne Therapeutics' BLA for Z-Rostudirsen in Duchenne Muscular Dystrophy with Priority Review
The U.S. Food and Drug Administration has accepted Dyne Therapeutics' Biologics License Application for z-rostudirsen, granting Priority Review and setting a target action date of January 21, 2027. The application seeks Accelerated Approval for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping, based on dystrophin as a surrogate endpoint. In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen once every four weeks led to a robust and statistically significant increase in dystrophin production, with functional improvement observed across multiple clinical endpoints and a favorable safety profile. Dyne expects a potential U.S. launch in the first quarter of 2027 if approval is received on the anticipated timeline. The company is also advancing four other development candidates targeting exons 53, 45, 44, and 55 for DMD.
TD Cowen Initiates Dyne Therapeutics With Buy Rating on Force Platform Potential
TD Cowen initiated coverage of Dyne Therapeutics with a Buy rating on June 26, citing the potential of its Force platform to improve drug delivery in neuromuscular and CNS diseases. The firm highlighted late-stage candidates z-basivarsen for myotonic dystrophy type 1 and z-rostudirsen for exon 51 Duchenne muscular dystrophy mutations as potential top-tier therapies. Separately, Dyne amended its non-dilutive senior secured term loan with Hercules Capital on June 17, receiving $50 million at closing and gaining the option to draw an additional $50 million tranche upon achieving certain milestones, while the final facility was expanded by $25 million to provide up to $125 million in capital at Hercules' discretion.
Dyne Therapeutics edges out Recursion Pharmaceuticals as the preferred speculative biotech buy for 2026
Dyne Therapeutics gets the nod over Recursion Pharmaceuticals as the better buy among development-stage pharma stocks in 2026, according to an analysis by The Motley Fool. Dyne, with a $3.7 billion market cap and no revenue, is preparing its first Duchenne muscular dystrophy treatment for a potential market entry in early fiscal 2027, with a second product expected in 2028, and analysts project sales could surpass $1 billion by 2030. Recursion, a $2 billion market cap company, generated $74.7 million in fiscal 2025 revenue from partnerships but saw a net loss of nearly $645 million, and its own product revenue is seen as years away despite a recent clinical proof of concept for its REC-4881 treatment. Both companies carry high risk, but Dyne appears closer to bringing a treatment to market.
Vertex Pharmaceuticals edges out Dyne Therapeutics as the better biotech buy for 2026
Vertex Pharmaceuticals is favored over Dyne Therapeutics as the better drug innovator stock for 2026, according to an analysis by The Motley Fool. Dyne Therapeutics is a clinical-stage company with no revenue, reporting a net loss of $446.2 million in fiscal 2025, while Vertex posted $12 billion in revenue and nearly $4 billion in net income. Vertex's cystic fibrosis portfolio now covers 95% of U.S. patients and is expanding globally, with a promising pipeline including povetacicept for IgA nephropathy. Dyne's first product for Duchenne muscular dystrophy is expected in early fiscal 2027, with analysts projecting $53 million in sales that year and over $1 billion by 2030. Despite Dyne's growth potential, Vertex's strong profitability, heavy R&D investment, and reasonable forward price-to-earnings ratio make it the preferred choice.
DYN · Capital · Negative Dyne Therapeutics is a clinical-stage company with no revenue and a net loss of $446.2 million, making it less attractive compared to Vertex
VRTX · Capital · Positive Vertex has strong profitability ($12B revenue, $4B net income), a promising pipeline, and a reasonable forward P/E ratio, making it the preferred biotech buy
Viking Therapeutics favored over Dyne Therapeutics for 2026 healthcare investment
The Motley Fool selects Viking Therapeutics over Dyne Therapeutics as the better healthcare stock for 2026, citing the massive obesity-treatment market opportunity for Viking's weight-loss candidate VK2735. Both clinical-stage biotechs reported zero revenue and widening net losses in fiscal 2025, with Dyne posting a loss of nearly $446.2 million and Viking close to $359.6 million. Viking carries no debt and holds a current ratio of roughly 9.3x, while Dyne has a debt-to-equity ratio of 0.19x and a current ratio of approximately 22.3x. The analysis notes Dyne's focus on rare neuromuscular diseases limits its market size, whereas Viking's phase 3 obesity program targets a far larger patient population despite competition from Eli Lilly and Novo Nordisk. Viking also faces an investigation into potential securities-law violations and relies on a license agreement with Ligand Pharmaceuticals.
VKTX · Demand · Positive The Motley Fool selects Viking as the better healthcare stock for 2026, citing its massive obesity-treatment market opportunity for VK2735.
DYN · Competition · Negative The Motley Fool selects Viking over Dyne, citing Dyne's focus on rare neuromuscular diseases limits its market size compared to Viking's obesity program.
LGND · Demand · Positive Viking relies on a license agreement with Ligand Pharmaceuticals, so Viking's potential success could benefit Ligand.
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics has appointed Barry Greene to its Board of Directors. Greene brings more than 30 years of biopharmaceutical experience, with expertise in rare diseases, neuroscience, and oncology. He currently serves as lead independent director at Karyopharm Therapeutics and previously was CEO of Sage Therapeutics from December 2020 to July 2025. Before that, he spent 20 years at Alnylam Pharmaceuticals, most recently as President and COO. Dyne shares closed Monday at $20.87, up 5.40%.
Dyne Therapeutics Grants Inducement Equity Awards to Six New Employees
Dyne Therapeutics has granted inducement equity awards to six newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards consist of non-statutory stock options to purchase up to an aggregate of 126,000 shares of common stock at an exercise price equal to the June 16, 2026 closing price, and restricted stock units covering an aggregate of 40,100 shares. The stock options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in 12 equal quarterly installments. The restricted stock units vest over four years in four equal annual installments, subject to continued service.
Dyne Therapeutics expands debt facility with Hercules Capital to up to $400 million
Dyne Therapeutics has amended its senior secured term loan facility with Hercules Capital, increasing total borrowing capacity to up to $400 million. The amendment provides an additional $125 million in potential funding, with $50 million drawn immediately at closing. A new $50 million tranche is available at Dyne's option upon achieving certain milestones, and the final tranche was increased by $25 million to up to $75 million, fundable at Dyne's request and Hercules' discretion. Including the $50 million just funded, Dyne has borrowed $200 million across three tranches and retains access to up to $200 million in future funding. The company plans to use the capital to advance its lead candidates, zeleciment rostudirsen for Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1, toward potential U.S. launches in the next two years.
USA